News archive
Showing 788 results
October 2020
-
Statement
New policy related to the 340B program
-
Media Release
Novartis STEP Program™ awards nearly $375,000 to patient advocacy organizations for their innovative solutions in biomarker testing; now accepting proposals for caregiving in cancer and certain blood disorders
The STEP (Solutions to Empower Patients) ProgramTM supports nonprofit organizations that deliver creative solutions to address barriers to care Five patient advocacy organizations were provided… -
Media Release
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
-
Media Release
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
Results presented at the Migraine Trust Virtual Symposium highlight long-term benefit of Aimovig Aimovig has the longest duration of safety and efficacy trial data for any anti-CGRP pathway…
September 2020
-
Statement
Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique
Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines. -
Story Education and Awareness
Day of Reflection at Novartis
On this Day of Reflection, Novartis associates are thinking and talking about what it means to be part of a truly diverse and inclusive organization.
-
Media Release
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
-
Media Release
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice Commitment to include… -
Media Release
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
-
Media Release
Novartis presents data at ACTRIMS-ECTRIMS on the effects of treatment with Mayzent® (siponimod) studied on disability progression and cognitive processing speed in patients with progressing relapsing multiple sclerosis
Subgroup post hoc analysis of EXPAND reported that Mayzent reduced the risk of cognitive worsening and improved the chance of cognitive improvement at 6 months versus placebo in patients with… -
Media Release
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and prolonged time to…